| Osteoprotegerin: a novel secreted protein involved in the regulation of bone density WS Simonet, DL Lacey, CR Dunstan, M Kelley, MS Chang, R Lüthy, ... cell 89 (2), 309-319, 1997 | 7077 | 1997 |
| Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation DL Lacey, E Timms, HL Tan, MJ Kelley, CR Dunstan, T Burgess, R Elliott, ... cell 93 (2), 165-176, 1998 | 6997 | 1998 |
| OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis YY Kong, H Yoshida, I Sarosi, HL Tan, E Timms, C Capparelli, S Morony, ... Nature 397 (6717), 315-323, 1999 | 4277 | 1999 |
| Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification N Bucay, I Sarosi, CR Dunstan, S Morony, J Tarpley, C Capparelli, ... Genes & development 12 (9), 1260-1268, 1998 | 2896 | 1998 |
| Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand H Hsu, DL Lacey, CR Dunstan, I Solovyev, A Colombero, E Timms, ... Proceedings of the National Academy of Sciences 96 (7), 3540-3545, 1999 | 2223 | 1999 |
| Increased bone formation in osteocalcin-deficient mice P Ducy, C Desbois, B Boyce, G Pinero, B Story, C Dunstan, E Smith, ... Nature 382 (6590), 448-452, 1996 | 2158 | 1996 |
| The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption LC Hofbauer, S Khosla, CR Dunstan, DL Lacey, WJ Boyle, BL Riggs Journal of bone and mineral research 15 (1), 2-12, 2000 | 1720 | 2000 |
| TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling MA Lomaga, WC Yeh, I Sarosi, GS Duncan, C Furlonger, A Ho, S Morony, ... Genes & development 13 (8), 1015-1024, 1999 | 1592 | 1999 |
| RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism J Li, I Sarosi, XQ Yan, S Morony, C Capparelli, HL Tan, S McCabe, ... Proceedings of the national academy of sciences 97 (4), 1566-1571, 2000 | 1433 | 2000 |
| Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of … LC Hofbauer, F Gori, BL Riggs, DL Lacey, CR Dunstan, TC Spelsberg, ... Endocrinology 140 (10), 4382-4389, 1999 | 1090 | 1999 |
| A single‐dose placebo‐controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women PJ Bekker, DL Holloway, AS Rasmussen, R Murphy, SW Martin, PT Leese, ... Journal of Bone and Mineral Research 20 (12), 2274-2282, 2005 | 1045 | 2005 |
| The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts TL Burgess, Y Qian, S Kaufman, BD Ring, G Van, C Capparelli, M Kelley, ... The Journal of cell biology 145 (3), 527-538, 1999 | 1041 | 1999 |
| Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells LC Hofbauer, S Khosla, CR Dunstan, DL Lacey, TC Spelsberg, BL Riggs Endocrinology 140 (9), 4367-4370, 1999 | 1028 | 1999 |
| Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells LC Hofbauer, DL Lacey, CR Dunstan, TC Spelsberg, BL Riggs, S Khosla Bone 25 (3), 255-259, 1999 | 860 | 1999 |
| Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis H Min, S Morony, I Sarosi, CR Dunstan, C Capparelli, S Scully, G Van, ... The Journal of experimental medicine 192 (4), 463-474, 2000 | 808 | 2000 |
| The effect of a single dose of osteoprotegerin in postmenopausal women PJ Bekker, D Holloway, A Nakanishi, M Arrighi, PT Leese, CR Dunstan Journal of Bone and Mineral Research 16 (2), 348-360, 2001 | 783 | 2001 |
| Calcification in atherosclerosis: bone biology and chronic inflammation at the arterial crossroads TM Doherty, K Asotra, LA Fitzpatrick, JH Qiao, DJ Wilkin, RC Detrano, ... Proceedings of the National Academy of Sciences 100 (20), 11201-11206, 2003 | 631 | 2003 |
| A phase I study of AMGN‐0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases JJ Body, P Greipp, RE Coleman, T Facon, F Geurs, JP Fermand, ... Cancer: Interdisciplinary International Journal of the American Cancer …, 2003 | 485 | 2003 |
| The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated F Gori, LC Hofbauer, CR Dunstan, TC Spelsberg, S Khosla, BL Riggs Endocrinology 141 (12), 4768-4776, 2000 | 474 | 2000 |
| Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma PI Croucher, CM Shipman, J Lippitt, M Perry, K Asosingh, A Hijzen, ... Blood, The Journal of the American Society of Hematology 98 (13), 3534-3540, 2001 | 459 | 2001 |
Peter PivonkaQueensland University of Technology, School of Mechanical, Medical and Process EngineeringVerified email at qut.edu.au
